ArticleNature medicine2018
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
2 registry-linked trialsAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 382 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
382citing papers in PubMed, 2 pooled it
21.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting
NCT06882057 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation
Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed Low Risk Childhood B-cell Acute Lymphoblastic Leukemia
Who cites it
382 citing papers in PubMed, 2 syntheses or guidelines pooled it, 547 citations in OpenAlex.
- Targeted therapies in pediatric B-Cell acute lymphoblastic leukemia: mechanisms, efficacy, and future directions.Frontiers in pharmacology · 2026Pooled it
- Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.Cancer medicine · 2023Pooled it
- Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL.EBioMedicine · 2025Trial
- Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.Frontiers of medicine · 2023Trial
- Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.Science advances · 2026Article
- Review
- Multi-dimensional orchestration of binders for improved CAR-T immunotherapy.Cancer letters · 2026Review
- Ultrasound controllable and antigen-independent killing viaMolecular therapy. Oncology · 2026Article
- CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.Leukemia · 2026Article
- Real-World Efficacy and Safety of Glofitamab-Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas.American journal of hematology · 2026Observational
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.Leukemia · 2026Article
- mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.Leukemia · 2026Article
- Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- Epigenetics as a mechanism of lineage extinction and relapse of B-cell lymphoma treated with CD19 CAR T-cell therapy.Blood neoplasia · 2026Article
- Article
- Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.European journal of haematology · 2026Review
- Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma.Molecular cancer therapeutics · 2026Article
- Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.Med (New York, N.Y.) · 2026Article
322 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
25 authors at 14 institutions in 7 countries.
Elena J OrlandoNovartis Institutes for BioMedical Research, Cambridge, MA, USA. elena.orlando@novartis.com.
Xia HanNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Catherine TribouleyNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Patricia A WoodNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Rebecca J LearyNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Markus RiesterNovartis Institutes for BioMedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4759-8332
John E LevineTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Muna QayedAflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA.
Stephan A GruppDivison of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Michael BoyerUniversity of Utah, Salt Lake City, UT, USA.
Barbara De MoerlooseDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
Eneida R NemecekOregon Health & Science University, Portland, OR, USA.
Henrique BittencourtSainte-Justine University Health Center, Montreal, Quebec, Canada.
Hidefumi HiramatsuDepartment of Pediatrics, Kyoto University, Kyoto, Japan.
Jochen BuechnerDepartment of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.
Stella M DaviesDivison of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Michael R VernerisDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Kevin NguyenNavigate BioPharma Services, Inc., A Novartis Subsidiary, Carlsbad, CA, USA.
Jennifer L BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Hans BitterNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Michael MorrisseyNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Piotr PierogNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.ORCID http://orcid.org/0000-0001-6711-4107
Serafino PantanoNovartis Pharma AG, Basel, Switzerland.
Jeffrey A EngelmanNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Wendy WincklerNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Novartis (United States) · USNovartis (Switzerland) · CHCentre Hospitalier Universitaire Sainte-Justine · CAChildren's Hospital of Philadelphia · USCincinnati Children's Hospital Medical Center · USEmory University · USGhent University Hospital · BEIcahn School of Medicine at Mount Sinai · USKyoto University · JPNavidea Biopharmaceuticals (United States) · USOregon Health & Science University · USOslo University Hospital · NOUniversity of Minnesota · USUniversity of Utah · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19
Indexed as
Antigens, CD19Drug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLoss of HeterozygosityMutationPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesAntigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06339255ClinicalTrials.gov
NCT06882057ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.